ClinicalTrials.gg
CompletedNCT02004964Updated Dec 11, 2018

Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation

An observational study in Type 1 Diabetes Mellitus, sponsored by Rodolfo Alejandro. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-12-11.

Sponsored by Rodolfo Alejandro · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Protocol to screen potential subjects for islet transplantation

Read the detailed description

Subjects with Type 1 diabetes and history of severe hypoglycemia will undergo screening similar to the screening done for islet transplantation including: history; physical; chest X rays; upper GI series if history of ulcer; abdominal and pelvic ultrasound with careful attention to liver parenchyma and gallbladder; EKG; stress echocardiography if older than 35, psychological evaluation; autonomic and sensorimotor evaluation. They will also have a tuberculosis skin test (PPD), and pre-transplant laboratory tests, including: serology (for hepatitis B and C, HTLV I and II, Herpesvirus 1 and 2, CMV, EBV, Parvovirus B19, RPR and HIV); first morning urine (albumin, protein and creatinine), GFR; urinalysis and urine culture; CBC, chemistry, PT, PTT, INR, C-peptide (basal and stimulated), HbA1c, , lipid profile, LFTs, thyroid profile, blood typing, PRA, MHC determination, auto-antibodies (GAD65, IA2 and insulin), and if male, prostate specific antigen (PSA). Severity of glucose lability and hypoglycemia unawareness is assessed with Clarke score, Lability index, Mage and hypoglycemia score.

I

02

Conditions studied

  • Type 1 Diabetes Mellitus
03

In context

Diabetes Mellitus, Type 1

3,614 studies on the registry are indexed under Diabetes Mellitus, Type 1; 586 are open to participants now.

This study's enrollment of 40 is below the median of 121 across 769 observational studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Rodolfo Alejandro is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with type 1 DM

Eligibility criteria

Inclusion Criteria:

  1. Patients between 18 and 65 years of age
  2. Patients with type 1 diabetes mellitus for more than 5 years duration
  3. Body Mass Index (BMI)
  4. Fulfill one or more of the following:

1. Manifest signs and symptoms that are severe enough to be incapacitating. Incapacitating signs and symptoms include hypoglycemic episodes requiring assistance by others and hypoglycemia unawareness, (the inability to recognize low blood glucoses; glucoses \<54 mg/dl); and/or 2. Patients with poor diabetes control (HbA1c > 8.0% but \< 12%), despite intensive insulin therapy, as defined by: self monitoring of blood glucose ≥ 4 times/day, and multiple insulin injections (≥ 3/day) or insulin pump, and close monitoring of blood glucose control by an Endocrinologist.; and/or 3. Progressive diabetic complications.

Exclusion Criteria: Potential candidates will be excluded as per following criteria:

  1. Age \<18 or >65 years;
  2. Duration of diabetes \<5 years;
  3. Do not have a physician that is monitoring diabetes for > 6 months;
  4. Body Mass Index >30
  5. Weight >80 kg;
  6. Insulin requirement >1.0 u/kg/d;
  7. HbA1C >12%;
  8. Stimulated or basal C-peptide >0.3 ng/ml;
  9. Iohexol GFR\<80
  10. Macroalbuminuria (>300 mg/24 hours);
  11. Anemia consistently lower than the normal range.
  12. Hyperlipidemia (fasting LDL cholesterol>130mg/dl and/or fasting triglycerides >200mg/dl);
  13. Abnormal liver function tests (consistently >1.5 x normal range);
  14. Serological evidence of HIV, HBsAg and/or HBcAb, HBsAb without history of vaccination, HTLV-1 or HCV;
  15. Negative serology for Epstein Barr virus (EBV) or evidence of acute or chronic infection (IgM≥IgG);
  16. Lack of updated immunizations per current CDC guidelines (including Lack of immunization against hepatitis B, pneumococcus and influenza - during season);
  17. Presence of panel reactive antibodies by flow cytometry
  18. Prostate specific antigen (PSA) >4 ng/ml unless malignancy ruled out;
  19. Positive tuberculin test (unless proof of adequate treatment can be provided);
  20. X-ray evidence of pulmonary infection or other significant pathology;
  21. Gall stones and/or portal hypertension and/or hemangioma on liver ultrasound;
  22. Abnormal abdominal or pelvic ultrasound (evidence of masses that are considered suspicious for malignancy or adenopathy);
  23. Active peptic ulcer disease;
  24. Active infections;
  25. Unstable cardiovascular status (including positive stress echocardiography if >age 35)/MI in the past 6 months/LVEF\<30%)
  26. Untreated or unstable proliferative diabetic retinopathy;
  27. Previous/concurrent organ transplantation (except failed islet cell / pancreas transplantation);
  28. Malignancy or previous malignancy;
  29. Any medical condition requiring chronic use of steroids;
  30. Active alcohol or substance abuse; smoking in the last 6 months;
  31. Sexually active females who are not: a) post-menopausal, b) surgically sterile, or c) not using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices with spermicide are acceptable; condoms used alone are not acceptable);
  32. Positive pregnancy test or intent for future pregnancy, or male subject's intent to procreate;
  33. Any condition or any circumstances that makes it unsafe to undergo an islet cell transplant;
  34. Psychogenically unable to comply;
  35. Failed psychological evaluation.
  36. Persistent leukopenia (white blood cell count \<3,000/uL on more than 3 occasions)
  37. Acute or chronic pancreatitis.
  38. Severe or unremitting diarrhea, vomiting or othe gastrointestinal disorder potentially interfering with the ability to absorb oral medications.
  39. Lymphopenia - \< 1,000/uL 40 Neutropenia - \<1,500/uL

41. Thrombocytopenia - \<100,000/uL

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
40 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. eligibility for islet transplantation

    This trial has the objective to determine subject eligibility for future islet transplant trials using fasting labs (including CBC, Chemistry, PRA, auto-antibodies, coagulation panel and others); a mixed meal tolerance test, psychological evaluation and a physical exam.

    Time frame: Baseline

07

Study locations

1 site
  • Diabetes Research Institute
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02004964
Lead sponsor
Rodolfo Alejandro
Responsible party
Rodolfo Alejandro (Professor of Medicine, University of Miami) — Sponsor-investigator
First posted
Dec 9, 2013
Start date
Apr 2009
Primary completion
Nov 6, 2018
Completion
Nov 6, 2018
Last update
Dec 11, 2018

Study contacts

Rodolfo Alejandro, MD
principal investigator · University of Miami

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion